{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T18:33:37Z","timestamp":1784918017931,"version":"3.55.0"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>We previously described that a short version of the acute octreotide test (sAOT) can predict the response to first-generation somatostatin receptor ligands (SRLs) in patients with acromegaly. We have prospectively reassessed the sAOT in patients from the ACROFAST study using current ultra-sensitive GH assays. We also studied the correlation of sAOT with tumor expression of E-cadherin and somatostatin receptor 2 (SSTR2) .<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 47 patients treated with SRLs for 6 months were evaluated with the sAOT at diagnosis and correlated with SRLs\u2019 response. Those patients whose IGF1 decreased to &amp;lt;3SDS from normal value were considered <jats:italic>responders<\/jats:italic> and those whose IGF1 was \u22653SDS, were considered <jats:italic>non-responders<\/jats:italic>. The 2 hours GH value (GH<jats:sub>2h<\/jats:sub>) after s.c. administration of 100 mcg of octreotide was used to define predictive cutoffs. E-cadherin and SSTR2 immunostaining in somatotropinoma tissue were investigated in 24\/47 and 18\/47 patients, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In all, 30 patients were responders and 17 were non-responders. GH<jats:sub>2h<\/jats:sub> was 0.68 (0.25-1.98) ng\/mL in responders vs 2.35 (1.59-9.37) ng\/mL in non-responders (p&amp;lt;0.001). GH<jats:sub>2h<\/jats:sub> = 1.4ng\/mL showed the highest ability to identify responders (accuracy of 81%, sensitivity of 73.3%, and specificity of 94.1%). GH<jats:sub>2h<\/jats:sub> = 4.3ng\/mL was the best cutoff for non-response prediction (accuracy of 74%, sensitivity of 35.3%, and specificity of 96.7%). Patients with E-cadherin-positive tumors showed a lower GH<jats:sub>2h<\/jats:sub> than those with E-cadherin-negative tumors [0.9 (0.3-2.1) vs 3.3 (1.5-12.1) ng\/mL; p&amp;lt;0.01], and patients with positive E-cadherin presented a higher score of SSTR2 (7.5 \u00b1 4.2 vs 3.3 \u00b1 2.1; p=0.01).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The sAOT is a good predictor tool for assessing response to SRLs and correlates with tumor E-cadherin and SSTR2 expression. Thus, it can be useful in clinical practice for therapeutic decision-making in patients with acromegaly.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1269787","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T15:40:26Z","timestamp":1698766826000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly"],"prefix":"10.3389","volume":"14","author":[{"given":"Montserrat","family":"Marques-Pamies","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Valassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betina","family":"Biagetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Gim\u00e9nez-Palop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Carrato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Pons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Villar-Taibo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Araujo-Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepci\u00f3n","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Sim\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreu","family":"Sim\u00f3-Servat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Xifra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Pav\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogelio","family":"Garc\u00eda-Centeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Zavala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia Alexandra","family":"Hanzu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Aulinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Vilarrasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soledad","family":"Librizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Calatayud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paz","family":"de Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Alvarez-Escola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pic\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Sampedro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Salinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Fajardo-Monta\u00f1ana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"C\u00e1mara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Bernab\u00e9u","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Jord\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Marazuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manel","family":"Puig-Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: A consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"key":"B2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3803\/EnM.2019.34.1.53","article-title":"Medical treatment with somatostatin analogues in acromegaly: position statement","volume":"34","author":"Chin","year":"2019","journal-title":"Endocrinol Metab (Seoul)."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-018-0058-5","article-title":"A Consensus Statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.endonu.2013.01.012","article-title":"Neuroendocrinology Group of the Spanish Society of Endocrinology and Nutrition. Practical guidelines for diagnosis and treatment of acromegaly","volume":"60","author":"Cordido","year":"2013","journal-title":"Endocrinol Nutr"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-017-0791-0","article-title":"Somatostatin receptor ligands in the treatment of acromegaly","volume":"20","author":"Gadelha","year":"2017","journal-title":"Pituitary"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2008.03441.x","article-title":"Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study","volume":"70","author":"Colao","year":"2009","journal-title":"Clin Endocrinol (Oxf)."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0027","article-title":"A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly","volume":"93","author":"Murray","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2021.12.017","article-title":"Personalized medical treatment of patients with acromegaly: A review","volume":"28","author":"Lim","year":"2022","journal-title":"Endocr Pract"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0260","article-title":"Long-acting somatostatin analog therapy of acromegaly: a meta-analysis","volume":"90","author":"Freda","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1210\/clinem\/dgab726","article-title":"The future of somatostatin receptor ligands in acromegaly","volume":"107","author":"Gadelha","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.23736\/S0391-1977.18.02937-1","article-title":"Precision medicine in the treatment of acromegaly","volume":"44","author":"Puig-Domingo","year":"2019","journal-title":"Minerva Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/cen.12731","article-title":"Treatment of acromegaly in the era of personalized and predictive medicine","volume":"83","author":"Puig Domingo","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ16-0175","article-title":"The value of an acute octreotide suppression test in predicting short-term efficacy of somatostatin analogues in acromegaly","volume":"63","author":"Wang","year":"2016","journal-title":"Endocr J"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2011.03982.x","article-title":"Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure","volume":"74","author":"Carlsen","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4103\/0022-3859.62421","article-title":"The value of an acute octreotide suppression test in predicting response to long-term somatostatin analogue therapy in patients with acromegaly","volume":"56","author":"Bandgar","year":"2010","journal-title":"J Postgrad Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1065339","article-title":"A short acute octreotide test for response prediction of long-term treatment with somatostatin analogues in acromegalic patients","volume":"40","author":"Halperin","year":"2008","journal-title":"Horm Metab Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02073","article-title":"The octreotide test dose is not a reliable predictor of subsequent response to somatostatin analogue therapy in patients with acromegaly","volume":"154","author":"Pokrajac","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1530\/eje.1.01935","article-title":"Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF1 normalization with Sandostatin LAR in acromegaly","volume":"153","author":"Herder","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2005.02.007","article-title":"Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly","volume":"15","author":"Biermasz","year":"2005","journal-title":"Growth Horm IGF Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2004.02191.x","article-title":"The value of an acute octreotide suppression test in predicting long term responses to depot somatostatin analogues in patients with active acromegaly","volume":"62","author":"Karavitaki","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2005.02278.x","article-title":"The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly","volume":"62","author":"Gilbert","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1590\/s0004-27302004000200007","article-title":"Usefulness of subcutaneous or long-acting octreotide as a predictive test and in the treatment of acromegaly","volume":"48","author":"Halah","year":"2004","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-005-1756-2","article-title":"Poor responses to a test dose of subcutaneous octreotide predict the need for adjuvant therapy to achieve \u201csafe\u201d growth hormone levels","volume":"7","author":"Lindsay","year":"2004","journal-title":"Pituitary"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1159\/000081418","article-title":"Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR","volume":"62","author":"Jenkins","year":"2004","journal-title":"Horm Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.81.6.8964877","article-title":"Prediction of efficacy of octreotide therapy in patients with acromegaly","volume":"81","author":"Colao","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1988.tb02890.x","article-title":"Therapy of acromegaly with sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical \u2018cure\u2019","volume":"29","author":"Lamberts","year":"1988","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/j.1365-2265.2011.04163.x","article-title":"Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly","volume":"76","author":"Fougner","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-18-0565","article-title":"Molecular profiling for acromegaly treatment: a validation study","volume":"27","author":"Puig-Domingo","year":"2020","journal-title":"Endocr Relat Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0573","article-title":"Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure","volume":"95","author":"Puig-Domingo","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B32","first-page":"989","article-title":"The volume of the sella turcica","volume":"87","author":"Di Chiro","year":"1962","journal-title":"Am J Roentgenol Radium Ther Nucl Med"},{"key":"B33","article-title":"Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue","volume":"8","author":"Remmele","year":"1987","journal-title":"Pathologe"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11061050","article-title":"Somatostatin receptor subtype expression in patients with acromegaly and complicated clinical course","volume":"11","author":"Pichler","year":"2021","journal-title":"Diagn (Basel)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2609","article-title":"Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly","volume":"98","author":"Gatto","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1515\/CCLM.2011.201","article-title":"Harmonization of growth hormone measurements with different immunoassays by data adjustment","volume":"49","author":"M\u00fcller","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.endinu.2018.01.008","article-title":"Criteria for diagnosis and postoperative control of acromegaly, and screening and management of its comorbidities: Expert consensus","volume":"65","author":"Bernabeu","year":"2018","journal-title":"Endocrinol Diabetes Nutr (Engl Ed)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2670","article-title":"A consensus on criteria for cure of acromegaly","volume":"95","author":"Giustina","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2022.101502","article-title":"Age, GH\/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: A clinicopathological study","volume":"67","author":"Durmu\u015f","year":"2022","journal-title":"Growth Horm IGF Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.984877","article-title":"Factors associated with therapeutic response in acromegaly diagnosed in the elderly in Spain","volume":"16","author":"Biagetti","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab125","article-title":"Machine learning-based prediction model for treatment of acromegaly with first-generation somatostatin receptor ligands","volume":"106","author":"Wildemberg","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B42","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1210\/jc.2005-1208","article-title":"Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly","volume":"91","author":"Colao","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14339","article-title":"Molecular determinants of enhanced response to somatostatin receptor ligands after debulking in large GH-producing adenomas","volume":"94","author":"Gil","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.16173","article-title":"Predictive and prognostic significance of tumour subtype, SSTR1-5 and e-cadherin expression in a well-defined cohort of patients with acromegaly","volume":"25","author":"Soukup","year":"2021","journal-title":"Cell Mol Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2145","article-title":"Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide","volume":"98","author":"Casar-Borota","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.646210","article-title":"Epithelial-mesenchymal transition in the resistance to somatostatin receptor ligands in acromegaly","volume":"12","author":"Gil","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1210\/en.2013-1051","article-title":"Epithelial splicing regulator protein 1 and alternative splicing in somatotroph adenomas","volume":"154","author":"Lekva","year":"2013","journal-title":"Endocrinology"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1760","article-title":"Gene expression profiling identifies ESRP1 as a potential regulator of epithelial mesenchymal transition in somatotroph adenomas from a large cohort of patients with acromegaly","volume":"97","author":"Lekva","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.13851","article-title":"E-cadherin expression is associated with somatostatin analogue response in acromegaly","volume":"23","author":"Venegas-Moreno","year":"2019","journal-title":"J Cell Mol Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2197","article-title":"The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response","volume":"95","author":"Fougner","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.20945\/2359-3997000000192","article-title":"Laboratory investigations in the diagnosis and follow-up of GH-related disorders","volume":"63","author":"Schilbach","year":"2019","journal-title":"Arch Endocrinol Metab"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1530\/EC-21-0175","article-title":"Reference values for IGF-I serum concentration in an adult population: use of the VARIETE cohort for two new immunoassays","volume":"10","author":"Sabbah","year":"2021","journal-title":"Endocr Connect"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1269787\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T15:40:33Z","timestamp":1698766833000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1269787\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,31]]},"references-count":52,"alternative-id":["10.3389\/fendo.2023.1269787"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1269787","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,31]]},"article-number":"1269787"}}